In Ayurveda, all dermatological disorders are described under the broad classification of Kustha Roga. Psoriasis is a common chronic inflammatory skin disorder and is closely comparable to Ekakustha as described in Ayurvedic texts. Ekakustha is characterized by features such as Aswedanam (absence of sweating), Mahavastu (extensive involvement of skin), and Matsyashakalopama (fish scale–like lesions with a shiny appearance), with predominance of Vata and Kapha Dosha. Although categorized under Kshudra Kustha, the disease significantly affects both physical and psychological well-being. This case report presents a 56-year-old female patient with a two-year history of large, pruritic, erythematous plaques with diffuse dry scaling involving most parts of the body. The patient had previously received irregular allopathic treatment from multiple dermatologists without significant relief. Based on clinical evaluation, the condition was diagnosed as psoriasis (Ekakustha). The patient was treated with Deepana–Pachana followed by Shamana Chikitsa, using Chandrashakladivatak internally and Navakkashaya Siddha Taila for external application for a duration of eight weeks. Clinical assessment before and after treatment revealed marked improvement in symptoms such as itching, scaling, erythema, and indurated plaques over the trunk and extremities. Additionally, significant improvement in psychological well-being and quality of life was observed. The findings suggest that Deepana–Pachana and Shamana Chikitsa, particularly the combination of Chandrashakladivatak and Navakkashaya Siddha Taila, may be effective in the management of psoriasis (Ekakustha) and may help in reducing disease activity and preventing further progression.
Keywords: Ayurveda, Chandrashakladivatak, Navakkashaya Siddha Taila, Psoriasis, Ekakustha.
How to cite this article: Tiwari RK, Ojha A, Tiwari N, Sharma A, Aklesh, Sharma M, Pandey A, A case report of the synergistic efficacy of Chandrashakladi vatak and Navak kashaya siddha tail in the management of psoriasis: A robust clinical experimental study. Int J Drug Deliv Technol. 2026;16(2s): 338-346; DOI: 10.25258/ijddt.16.338-346